English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduReporters are invited to this briefing about research from the Wilmot Cancer Institute at the University of Rochester Medical Center, with a new study to be published in the New England Journal of Medicine (NEJM).
Tag: non-Hodgkin lymphoma
ASCO: New ‘Armored’ CAR produces significant responses in patients whose cancers don’t respond to current CAR T cell therapies
A new “armored” form of CAR T cell therapy may be able to help patients with non-Hodgkin lymphoma whose cancers do not respond to currently available CAR T cell therapies. The Phase I clinical trial was presented at the 2024 ASCO Annual Meeting.
Researchers seek to improve success of chimeric antigen receptor-T cell therapy in non-Hodgkin lymphoma
A study published by researchers from Mayo Clinic Cancer Center at Mayo Clinic in Florida and Case Western, Cleveland Medical Center, investigates the reasons for decreasing remission rates for patients with non-Hodgkin lymphoma treated with chimeric antigen receptor-T cell therapy (CAR-T cell therapy).
Cancer cases are rising in adolescents and young adults
Cancer cases in adolescents and young adults have risen by 30% during the last four decades, with kidney cancer rising at the greatest rate, according to researchers at Penn State College of Medicine.
Early clinical trial supports tumor cell–based vaccine for mantle cell lymphoma
A phase I/II clinical trial by researchers at Stanford University suggests that vaccines prepared from a patient’s own tumor cells may prevent the incurable blood cancer mantle cell lymphoma (MCL) from returning after treatment. The study, which will be published June 19 in the Journal of Experimental Medicine (JEM), reveals that the vaccines are a safe and effective way to induce the body’s immune system to attack any tumor cells that could cause disease relapse.
CD19 CAR NK-cell therapy achieves 73% response rate in patients with leukemia and lymphoma
According to results from a Phase I/IIa trial at The University of Texas MD Anderson Cancer Center, treatment with cord blood-derived chimeric antigen receptor (CAR) natural killer (NK)-cell therapy targeting CD19 resulted in clinical responses in a majority of patients with relapsed or refractory non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL), with no major toxicities observed.
Study shows protein inhibitor as potential treatment approach for common mutations found in non-Hodgkin lymphomas
Study shows protein inhibitor as potential treatment approach for common mutations found in non-Hodgkin lymphomas. Findings may create immunotherapy options for lymphomas caused by CREBBP mutations.
Retrospective Analysis Identifies Need for Better Classification of Rare Lymphoma
In what is believed to be one of the largest studies of a rare disorder known as primary cutaneous gamma delta T-cell lymphoma, Rutgers Cancer Institute
investigators and other collaborators examined characteristics, treatment patterns and outcomes and determined accurate diagnosis of the disease requires ongoing analysis.
Calcium Signaling Identified as Exploitable Target in Addressing Drug Resistance to Non-Hodgkin Lymphoma Treatment
Gene expression profiling and other analyses conducted by Rutgers Cancer Institute of New Jersey researchers and colleagues examining drug resistance to a common antibody therapy for non-Hodgkin lymphoma have identified calcium signaling as a novel and exploitable target in overcoming this treatment obstacle. Results are being presented at the American Society of Hematology Annual Meeting.